In the last 15 to 20 years, there has been an explosion of interest in the area of lymphomas. Although the interest has continued to increase, the results of treatment have not particularly changed over the last ten years. Progressive confusion and increasing differences of opinion from many putative experts have resulted in a somewhat frenetic attitude on the part of many physicians. Indeed, the dogma set forth by many seems almost inversely proportional to the experience of those investigating these diseases.
In the past, I have personally taken the point of view that certain aspects of the non-Hodgkin's lymphomas have assumed the qualities of a surrealistic fantasy, as if written by Lewis Carroll. Thus, this paper will focus on certain aspects of the non-Hodgkin's lymphomas from the viewpoint of one who has always enjoyed both Alice in Wonderland and Through the Looking Glass.
What is a tea party? Natural history of non-Hodgkin's lymphomas and their unnatural (treated) history The concept of a non-disease is one that would have tickled Lewis Carroll from the beginning. It becomes mandatory to ask the question, 'Why do we categorize such illnesses as non-Hodgkin's lymphomas?' In my own opinion, this goes back approximately 30 years, when all these illnesses were thought to be incurable. The lesson of the late 1950s and early 1960swas that patients who had indentifiable Reed-Sternberg cells and were categorized as Hodgkin's disease could clearly be cured in some instances. Moreover, on the whole these patients with Hodgkin's disease tended to be a younger age group, they tended to have more systemic symptoms at presentation, they tended to have a more predictable illness in terms of lymphatic spread and relatively modest amounts of extranodal disease, and they tended to have peculiar immune deficits that appeared distinguishable from the rest of the lymphomas that we now categorize as non-Hodgkin's lymphomas.
Certainly, the non-Hodgkin's lymphomas as a group have a remarkable propensity to spread beyond the lymphatic system and especially to involve the bone marrow. There are also marked increases in the probabilities of mesenteric node involvement, Waldeyer's ring involvement, and central nervous system involvement, not only at presentation but throughout the course of the illness, compared to patients with Hodgkin's disease. It has long been recognized that the illness in some of these patients runs an amazingly indolent course for prolonged periods of time; and, in some instances, relatively modest amounts of treatment appear to control their illness for many years. These observations appeared to distinguish this group of lymphomas from the group we call Hodgkin's disease, which, on the whole, used to run a comparatively fulminant course over a matter offive years without treatment'.
With modern treatments, the curability of the Hodgkin's patient has become established as an absolute and unequivocal fact. This can be attributed to the work of many people; certainly Dr Finzi ranks with the names of Gilbert, Peters, and Kaplan as prominent radiologists who contributed mightily to our understanding of and approach to treating these illnesses. In the present era, the development of chemotherapy clearly represents a major step forward, with unequivocal cure being achieved in many patients having lymphomas with aggressive histology.
Paradoxically, patients with indolent histology have a much greater probability of presenting with advanced stage lymphomas (Stage III and IV) than do those with aggressive histology. Despite the fact that they present with illness of more advanced stage, they tend to run a much more indolent course in terms of outcome". Their survival is unequivocally greater for the first five to ten years, although their true curability is still a matter of considerable discussion and debate among many experts of widely differing points of view.
Having already emphasized the potential that these lymphomas have to extend into other extralymphatic sites, I must also emphasize that the major sites of relapse are still lymph nodes. This appears to be true whether patients have been treated with chemotherapy! or radiation therapy", If treated with the latter, then the sites of the lymph nodes that relapse are typically outside the radiation portals; if treated with chemotherapy, the sites of nodal relapse are usually sites of previous involvement".
Indeed, among malignant diseases one can state the truism that lymphomas are about lymph nodes. The leukaemias are primary bone marrow diseases characterized by intermittent and frequently fulminant systemic symptoms, with peculiar predispositions to infection, bleeding, and, paradoxically, thrombotic phenomena. Solid tumours are clinically characterized by a course manifesting symptoms predominantly from the site of the primary and from secondary end organ failure in liver, brain.Iungs, etc. Lymph node involvement in solid tumours, while common and important to prognosis and treatment strategies, is not a common tumour symptom that patients manifest clinically. But in the lymphomas, most patients have much of their symptomatic clini-cal course as a direct reflection of nodal involvement, even when extralymphatic involvement is present. Thus, lymphomas are about lymph nodes.
Tweedle Dum and Tweedle Dee
Histopathological confusion of classification systems of the non-Hodgkin's lymphomas In my opinion, much of the confusion in the area of the non-Hodgkin's lymphomas rests with the wide variety and range of histopathological classification systems that have evolved to describe the pathological groupings of these illnesses. There are at least six major classification systems, plus a formulation recently proposed". Most of these claim superiority, which has never been documented over the other systems.
Certainly, any classification system should be easy to learn, relatively easy to teach, reproducible, and have clinical correlations that make them clinically useful. In general, the reproducibility factor has been poorly assessed. A recent attempt to evaluate the reproducibility by having individual pathologists review the same slide twice on a random basis demonstrated a tremendous variance, ranging from 15% to as high as 50% in the hands of some pathologists". If the reproducibility of this phenomenon is as widely ranging as that, then it calls into serious question some of the classification systems that have not been well studied in terms of their reproducibility nor in terms of their clinicopathological usefulness. There is a need for classification systems that are scientifically relevant, but their reproducibility and usefulness are probably even more important. Some of the subtle histopathological parameters that are frequently described by some pathologists lack clear clinical relevance. Nonetheless, their use as the basis for further subdivisions ofdubious distinctions only adds to the confusion of the non-Hodgkin's lymphomas.
We are presently in transition in terms of classification as we become more technologically, immunologically, and molecularly oriented. As these newer laboratory tests become more reproducible and more established, I believe the long-range accomplishments of classification systems will be based more on these types of evaluations than on classic morphological interpretations, which lend themselves to capriciousness and excessive subjectivity.
The caucus race
Problems of staging To the radiation oncologist, staging refers to the discipline ofdefining a neoplastic disease in terms of its anatomical extent. Once the stage has been determined, then comparisons can be made between and among differing institutions; because there is also a crude correlation with prognosis, it allows one to prognosticate. On the other hand, there are oncologists today who believe that staging is coming up with a numerical or letter score that then determines the treatment for the patient (and for the physician).
Within any staging category there is a range of prognoses depending on a host of factors. Although stage is the most important single prognostic factor in predicting for an individual patient, there are many other important factors: age, sex, numbers and types of sites of involvement, sites of truly bulky disease, factors that go into salvage treatments, prior treatments, other medical illnesses, and consider-Journal ofthe Royal Society of Medicine Volume 80 February 1987 71 ations of the possible long-term toxicities of treatment. Any or all of these factors can be very important for anyone patient. When patients are grouped together within anyone-stage category, some of the subtleties among patients become smeared out by the very nature of the grouping system. Although various prospective studies may be predicated on stage as the basis for treatment selection, this fact represents more a political reality in designing prospective studies that some inherently mystical attribute of a staging classification. Moreover, the staging oflymphoma, as put forth at the Rye meeting in New York in the mid-1960s 7 and more recently in the Ann Arbor staging classification of the 1970s s, is really quite different from the staging classification for most other neoplastic diseases. For most neoplasms, the stage is a reflection of the bulk size of the primary mass or some indicator of the invasiveness of the tumour. By contrast, the staging for lymphoma is a numerical system that reflects the gross distribution of involved lymph nodes with respect to the diaphragm. There is nothing particularly crucial about the diaphragm; everybody has one, and it is conveniently located in approximately the midplane of the torso. Moreover, the supradiaphragmatic lymph node regions and the infradiaphragmatic lymph node regions constitute a volume that is approximately the maximal size that could be treated with modern radiation therapy equipment. Thus, the influence of radiation therapy on the staging system is very important in a practical sense. Strictly speaking, the staging classification system was intended for Hodgkin's disease; like most aspects of the lymphomas, it has been extrapolated to the non-Hodgkin's lymphomas.
With modern technology, it is becoming progressively more complex to decide what staging studies are really needed for anyone patient or what studies are needed to do an investigation or clinical trial. We have a wide variety of imaging techniques, many of which appear to duplicate and confirm each other. One can question whether patients always need liver/spleen scans, gallium scans, lymphangiograms, CT scans, MRI scans, and ultrasound. One can question how much routine CT and linear tomograpy add to a completely normal chest X-ray; in my own opinion, it is very little. The point is that there is no unanimity of opinion concerning what studies are truly needed. While this may vary from individual to individual, Table 1 shows the studies that I personally believe are essential for studying a patient prior to staging, and in addition lists the other studies that may be useful on an individual basis, but that I personally do not consider to be routine for all patients. From time to time, one has to be reminded that all these tests are really quite expensive and that in our desire to do everything possible to determine the stage of the patient, short of a laparotomy, the time required to stage the patient in a busy department sometimes begins to approach the duration of treatment required! Hence, my view that the staging process today is much like the 'caucus race' from Alice in Wonderland; there seems to be no clear start and no clear finish. Frequently, one seems to be going in circles and exactly who wins is not always apparent.
Beware of the Jabberwocky
Problems with treatment The modern treatment of non-Hodgkin's lymphomas has become extraordinarily complicated. For patients with aggressive histology, the impact of chemotherapy cannot be overestimated. Even in early stage disease, its value seems unequivocal when applied to large numbers of patients". Certainly, the major development of the 1970s in lymphomas was the recognition that among patients with advanced stage and aggressive histology there is a proportion who can be cured by intensive chemotherapy 810ne 1o. Despite this unequivocal accomplishment, the precise degree of success achieved is unclear, since many recent euphoric reports have a median follow up of two years or less. Although it is true that the large majority of relapses are seen within the first two years following completion of therapy, the physician experienced with these diseases will consider a report with such a short follow up as premature; he knows that some late relapses will occur regardless of how the patient was treated. The prematurity of such reports can be considered confirmed when several years pass without a published update.
On the other hand, the indolent histology patients have remained a major challenge. Intensive chemotherapy has a high probability ofinducing a complete remission, but the durability of those remissions appears to be modest at best, and the evidence for cure is really inconclusive. Thus, one can make a case for conservative 'watch and wait' type treatment in the indolent histology patients!", just as one can make a case for single-agent chemotherapy, multiagent chemotherapy, radiation to involved lymph nodes and total lymph node irradiation for Stages I through III, or even total body irradiation.
One of the more. interesting aspects of treatment has been the reluctance to conduct combined modality studies in patients with non-Hodgkin's lymphomas, despite the complementary patterns of relapse. The reasons are not entirely clear, but appear to reflect a lack of unanimity by 'aggressive' radiation therapists and 'aggressive' chemotherapists in deciding how to treat the patient. In addition, there have been major problems in terms of the long-term side effects of combined modality treatment in Hodgkin's disease patients.
Inasmuch as most of the strategies for non-Hodgkin's lymphomas have represented extrapolations from the results of treatment in Hodgkin's disease, it is worthwhile to note that, although the risk of induced neoplasia and leukaemia is certainly a major concern in Hodgkin's disease patients, the risk of this phenomenon in the non-Hodgkin's patients is harder to define. Part of this confusion is because of a finite risk of leukaemias other than myelogenous in the non-Hodgkin's patients that can reflect the natural history of the lymphomas. In addition, the myelogenous leukaemia reported in Hodgkin's disease may well represent exposure to alkylating agents and procarbazine, complicated further by exposure to ionizing radiation and probably an age factor!". In the non-Hodgkin's patients, procarbazine is an uncommon agent; thus an increased risk of induced neoplasia, especially leukaemia, is still one of more speculation than fact. Certainly, almost every physician who cares for any significant number of these patients has an anecdote concerning leukaemia in non-Hodgkin's patients. Yet, much of that is a reflection of the prolonged alkylating agent therapy for various courses of treatment that so many of the indolent histology patients receive throughout their illness13. Whether the risk of leukaemia in non-Hodgkin's lymphomas reaches the same proportion as it is thought to reach in Hodgkin's disease remains to be seen. Even the risk of leukaemia in Hodgkin's disease may be something of a distortion, since it is heavily based on actuarial projectionsI2.14.ls. The absolute numbers represent approximately 1% to 2%. On the other hand, because these figures are projected actuarially with variable periods of follow up, the estimate turns out to be 0.5% to 1% per year of follow up. It is still unclear if this actuarial projection will in fact continue to increase with time or whether it will eventually plateau out.
The vanishing Cheshire cat Future directions of treatment Since modern chemotherapy and modern radiotherapy have had impact on these diseases, where can we anticipate future directions for investigation? Obviously, it is difficult to predict, but I believe that between now and the end of the century developments will occur that will markedly diminish and possibly eliminate the present roles of chemotherapy and radiotherapy.
I have considerable enthusiasm for (but no direct experience of) the production of radiolabelled monoclonal antibodies. This type of treatment offers improvement of several orders of magnitude in the therapeutic ratio, even though it must be acknowledged that such monoclonal antibodies are only relatively specific.
The potential power of such treatment is illustrated by the remarkable case reported by Miller et al. 16 in which a heavily pretreated patient achieved a durable remission with anti-idiotypic antibody alone. The fact that such a response has not since been duplicated by these investigators or others suggests that a toxin or radioisotope will have to be con- jugated to the antibody for most patients, probably by means of a chelating agent. The isotope has more appeal than a toxin since one does not expect all tumour cells to express antigen, only most of them.
Using an isotope as the cytotoxic agent means that the isotope must only be close to the cell, whereas the toxin must be internalized within each cell to do its killing. Some of the potential pitfalls of this approach are listed in Table 2 . The list is not meant to be exhaustive but simply to focus on some obvious areas of future research. As long as lymphoid tumours manifest surface markers, this approach has considerable theoretical appeal.
Radioactive iodine has been used most frequently for diagnosis and therapy; although it is suitable for imaging, it is certainly not ideal for therapy. It has been used because it can be relatively easily attached to protein molecules directly. Unfortunately, it can also be easily deiodinated as well. Other isotopes, including beta and alpha emitters, will probably necessitate a chelating agent to link the isotope to the antibody molecule, Obviously the conjugate must be very stable in vivo and yet it must not compromise the binding to the antigen in any significant way. Purity ofreactions is important since small amounts of non-radioactive isotope material can greatly diminish the amount of radioactivity that can be chelated to antibody.
These potential pitfalls represent new frontiers in the investigation and treatment of the lymphomas. Some of these areas represent immune challenges, others represent nuclear medicine, but some are issues basic to radiation therapy and to radiobiology. As these challenges are overcome, the research promises to make the Cheshire cat of conventional Journal of the Royal Society of Medicine Volume 80 February 1987 73 therapy diminish in its importance and possibly disappear ultimately. In my opinion, it marks the next major step in the management of the non-Hodgkin's lymphomas. Curiouser, and curiouser!
